Advertisement

Changing Patterns of Prophylaxis and Treatment of Bacterial and Viral Intestinal Infections

  • Saurabh Mehandru
  • Edmund J. Bini
  • Douglas T. Dieterich

Abstract

Intestinal infections are a significant cause of mor- bidity and mortality in patients with human immun- odeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). The introduc- tion of highly active antiretroviral therapy (HAART) has significantly improved survival in HIV-infected patients [1–4]. With HAART, it is now possible to reconstitute the immune system, even in patients with advanced AIDS. As a result of HAART-induced increases in CD4 lymphocyte counts and decreases in HIV viral loads, there has been a dramatic reduction in the incidence of opportunistic intestinal infections and chronic diarrhea in HIV-infected patients [5–9]. Furthermore, treatment with potent antiretroviral therapy has increased the response to pathogen-spe- cific and empiric antidiarrheal therapy, decreased the incidence of recurrent diarrhea, and improved long- term survival in these individuals [5].

Keywords

Human Immunodeficiency Virus Infection Mycobacterium Avium Complex Yersinia Enterocolitica Cytomegalovirus Retinitis Oral Ganciclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Powderly WG, Landay A, Lederman MM (1998) Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 280:72–77PubMedCrossRefGoogle Scholar
  2. 2.
    Palella FJ Jr., Delaney KM, Moorman AC, et al(1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338:853–860PubMedCrossRefGoogle Scholar
  3. 3.
    Jacobson MA, French M (1998) Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. Aids 12 [Suppl] A:S157–S163PubMedCrossRefGoogle Scholar
  4. 4.
    Deeks SG, Smith M, Holodniy M, et al(1997) HIV-i protease inhibitors. A review for clinicians. JAMA 277:145–153PubMedCrossRefGoogle Scholar
  5. 5.
    Bini EJ, Cohen J (1999) Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected patients with chronic diarrhea. Am J Gas-troenterol 94:3553–3559CrossRefGoogle Scholar
  6. 6.
    Foudraine NA, Weverling GJ, Van Gool T, et al(1998) Improvement of chronic diarrhoea in patients with advanced HIV-i infection during potent antiretroviral therapy. AIDS 12:35–41PubMedCrossRefGoogle Scholar
  7. 7.
    Conteas CN, Berlin OG, Speck CE, et al(1998) Modifi-cation of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syn-drome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 58:555–558PubMedGoogle Scholar
  8. 8.
    Carr A, Marriott D, Field A, et al(1998) Treatment of HIV-i-associated microsporidiosis and cryp-tosporidiosis with combination antiretroviral therapy. Lancet 351:256–261PubMedCrossRefGoogle Scholar
  9. 9.
    Monkemuller KE, Call SA, Lazenby AJ, et al(2000) Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral thera-py. Am J Gastroenterol 95:457–462PubMedGoogle Scholar
  10. 10.
    Anonymous (2001) 2001 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2:493–554CrossRefGoogle Scholar
  11. 11.
    Guerrant RL, Van Gilder T, Steiner TS, et al(2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331–351PubMedCrossRefGoogle Scholar
  12. 12.
    Banerjee S, Lamont JT (2000) Treatment of gastroin-testinal infections. Gastroenterology 118:S48–S67PubMedCrossRefGoogle Scholar
  13. 13.
    Lew EA, Poles MA, Dieterich DT (1997) Diarrheal dis-eases associated with HIV infection. Gastroenterol Clin North Am 26:259–290PubMedCrossRefGoogle Scholar
  14. 14.
    Mehandru S, Bini EJ (2001) Small intestinal infections. Curr Treat Options Gastroenterol 4:149–162PubMedCrossRefGoogle Scholar
  15. 15.
    Dupont HL (1997) Guidelines on acute infectious diar-rhea in adults. The practice parameters committee of the American college of gastroenterology. Am J Gas-troenterol 92:1962–1975Google Scholar
  16. 16.
    Gruenewald R, Blum S, Chan J (1994) Relationship between human immunodeficiency virus infection and salmonellosis in 20-to 59-year-old residents of New York City. Clin Infect Dis 18:358–363PubMedCrossRefGoogle Scholar
  17. 17.
    Wilcox MH, Spencer RC (1992) Quinolones and sal-monella gastroenteritis. J Antimicrob Chemother 30:221–228PubMedCrossRefGoogle Scholar
  18. 18.
    Kovacs JA, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342:1416–1429PubMedCrossRefGoogle Scholar
  19. 19.
    Dupont HL (1993) Quinolones in Salmonella typhi infection. Drugs 45 [Suppl 31:119–124Google Scholar
  20. 20.
    Mermin JH, Townes JM, Gerber M, et al(1998) Typhoid fever in the united states, 1985-1994: changing risks of international travel and increasing antimicro-bial resistance. Arch Intern Med 158:633–638PubMedCrossRefGoogle Scholar
  21. 21.
    Acharya G, Butler T, Ho M, et al(1995) Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chlo-ramphenicol. Am J Trop Med Hyg 52:162–165PubMedGoogle Scholar
  22. 22.
    Hung CC, Hsieh SM, Hsiao CF, et al(2001) Risk of recurrent non-typhoid salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in aids patients in the era of highly active antiretroviral therapy. AIDS 15:645–647PubMedCrossRefGoogle Scholar
  23. 23.
    Baskin DH, Lax JD, Barenberg D (1987) Shigella bac-teremia in patients with the acquired immune defi-ciency syndrome. Am J Gastroenterol 82:338–341PubMedGoogle Scholar
  24. 24.
    Stoll BJ, Glass RI, Huq MI, et al(1982) Epidemiologic and clinical features of patients infected with shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 146:177–183PubMedCrossRefGoogle Scholar
  25. 25.
    Bennish ML (1991) Potentially lethal complications of shigellosis. Rev Infect Dis 13[Suppl 4]:S319–S324PubMedCrossRefGoogle Scholar
  26. 26.
    Haltalin KC, Nelson JD, Ring R III, et al(1967) Double-blind treatment study of shigellosis comparing ampi-cillin, sulfadiazine, and placebo. J Pediatr 70:970–981PubMedCrossRefGoogle Scholar
  27. 27.
    Bennish ML, Salam MA, Hossain MA, et al(1992) Antimicrobial resistance of shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sul-famethoxazole, and nalidixic acid. Clin Infect Dis 14:1055–1060PubMedCrossRefGoogle Scholar
  28. 28.
    Bennish ML, Salam MA, Khan WA, et al(1992) Treat-ment of shigellosis: iii. comparison of one-or two-dose ciprofloxacin with standard 5-day therapy. A ran-domized, blinded trial. Ann Intern Med 117:727–734PubMedGoogle Scholar
  29. 29.
    Kabir I, Butler T, Khanam A (1986) Comparative effi-cacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 29:645–648PubMedCrossRefGoogle Scholar
  30. 30.
    Salam MA, Bennish ML (1991) Antimicrobial therapy for shigellosis. Rev Infect Dis 13[Suppl 4]:S332–S341PubMedCrossRefGoogle Scholar
  31. 31.
    Nelson MR, Shanson DC, Hawkins D, et al(1991) Shigella in HIV infection. AIDS 5:1031–1032PubMedCrossRefGoogle Scholar
  32. 32.
    Sorvillo FJ, Lieb LE, Waterman SH (1991) Incidence of campylobacteriosis among patients with AIDS in Los Angeles county. J Acquir Immune Defic Syndr 4:598–602PubMedGoogle Scholar
  33. 33.
    Tee W, Mijch A (1998) Campylobacter jejuni bac-teremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review. Clin Infect Dis 26:91–96PubMedCrossRefGoogle Scholar
  34. 34.
    Smith KE, Besser JM, Hedberg CW, et al(1999) Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 340:1525–1532PubMedCrossRefGoogle Scholar
  35. 35.
    Manfredi R, Calza L, Chiodo F (2002) Enteric and dis-seminated Campylobacter species infection during HIV disease: a persisting but significantly modified association in the HAART era. Am J Gastroenterol 97:510–511PubMedCrossRefGoogle Scholar
  36. 36.
    Lorber B (1997) Listeriosis. Clin Infect Dis 24:1–9PubMedCrossRefGoogle Scholar
  37. 37.
    Armstrong RW, Fung PC (1993) Brainstem encephali-tis (rhombencephalitis) due to Listeria monocyto-genes: case report and review. Clin Infect Dis 16:689–702PubMedCrossRefGoogle Scholar
  38. 38.
    Mainardi JL, Lacassin F, Guilloy Y, et al(1998) Low rate of Clostridium difficile colonization in ambulato-ry and hospitalized HIV-infected patients in a hospital unit: a prospective survey. J Infect 37:108–111PubMedCrossRefGoogle Scholar
  39. 39.
    Demarais PL, Gertzen J, Weinstein RA (1997) Nosoco-mial infections in human immunodeficiency virus-infected patients in a long-term-care setting. Clin Infect Dis 25:1230–1232PubMedCrossRefGoogle Scholar
  40. 40.
    Barbut F, Meynard JL, Guiguet M, et al(1997) Clostrid-ium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 16:176–181PubMedCrossRefGoogle Scholar
  41. 41.
    Cappell MS, Philogene C (1993) Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infec-tion: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. Am J Gastroenterol 88:891–897PubMedGoogle Scholar
  42. 42.
    Lu SS, Schwartz JM, Simon DM, et al(1994) Clostridi-um difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 89:1226–1229PubMedGoogle Scholar
  43. 43.
    Teasley DG, Gerding DN, Olson MM, et al(1983) Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diar-rhoea and colitis. Lancet 2:1043–1046PubMedCrossRefGoogle Scholar
  44. 44.
    Anastasi JK, Capili B (2000) HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control 28:262–266PubMedCrossRefGoogle Scholar
  45. 45.
    Tacconelli E, Tumbarello M, De Gaetano DK, et al (1999) Clostridium difficile-associated diarrhea in human immunodeficiency virus infection—a chang-ing scenario. Clin Infect Dis 28:936–937PubMedCrossRefGoogle Scholar
  46. 46.
    Cover TL, Aber RC (1989) Yersinia enterocolitica. N Engl J Med 321:16–24PubMedCrossRefGoogle Scholar
  47. 47.
    Cohen JI, Rodday P (1989) Yersinia enterocolitica bac-teremia in a patient with the acquired immunodefi-ciency syndrome. Am J Med 86:254–255PubMedCrossRefGoogle Scholar
  48. 48.
    Flament-Saillour M, De Truchis P, Risbourg M, et al (1994) Yersinia enterocolitica peritonitis in a patient infected with the human immunodeficiency virus. Clin Infect Dis 18:655–656PubMedCrossRefGoogle Scholar
  49. 49.
    Pai CH, Gillis F, Tuomanen E, et al(1984) Placebo-controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis. J Pediatr 104:308–311PubMedCrossRefGoogle Scholar
  50. 50.
    Preston M, Brown S, Borczyk A, et al(1995) Antimi-crobial susceptibility of pathogenic Yersinia enteroco-litica isolated in Canada from 1972 to 1990. Contrib Microbiol Immunol 13:175–179PubMedGoogle Scholar
  51. 51.
    Stolk-Engelaar V, Meis J, Mulder J, et al(1995) Activi-ty of 24 antimicrobials against Yersinia enterocolitica. Contrib Microbiol Immunol 13:172–174PubMedGoogle Scholar
  52. 52.
    Wanke CA, Mayer H, Weber R, et al(1998) Enteroag-gregative Escherichia coli as a potential cause of diar-rheal disease in adults infected with human immun-odeficiency virus. J Infect Dis 178:185–190PubMedCrossRefGoogle Scholar
  53. 53.
    Mayer HB, Wanke CA (1995) Enteroaggregative Escherichia coli as a possible cause of diarrhea in an HIV-infected patient. N Engl J Med 332:273–274PubMedCrossRefGoogle Scholar
  54. 54.
    Wanke CA, Gerrior J, Blais V, et al(1998) Successful treatment of diarrheal disease associated with enteroag-gregative Escherichia coli in adults infected with human immunodeficiency virus. J Infect Dis 178:1369–1372PubMedCrossRefGoogle Scholar
  55. 55.
    Cohen J, West AB, Bini EJ (2001) Infectious diarrhea in human immunodeficiency virus. Gastroenterol Clin North Am 30:637–664PubMedCrossRefGoogle Scholar
  56. 56.
    Chan IS, Neaton JD, Saravolatz LD, et al(1995) Fre-quencies of opportunistic diseases prior to death among HIV-infected persons, community programs for clinical research on AIDS. AIDS 9:1145–1151PubMedCrossRefGoogle Scholar
  57. 57.
    Sepkowitz KA (1998) Effect of HAART on natural his-tory of AIDS-related opportunistic disorders. Lancet 351:228–230PubMedCrossRefGoogle Scholar
  58. 58.
    Race EM, Adelson-Mitty J, Kriegel GR, et al(1998) Focal mycobacterial lymphadenitis following initia-tion of protease-inhibitor therapy in patients with advanced HIV-i disease. Lancet 351:252–255PubMedCrossRefGoogle Scholar
  59. 59.
    Benson CA, Williams PL, Cohn DL, et al(2000) Clar-ithromycin or rifabutin alone or in combination for primary prophylaxis of mycobacterium avium com-plex disease in patients with AIDS: a randomized, dou-ble-blind, placebo-controlled trial. The aids clinical trials group 196/Terry Beirn community programs for clinical research on aids 009 protocol team. J Infect Dis 181:1289–1297PubMedCrossRefGoogle Scholar
  60. 60.
    Pierce M, Crampton S, Henry D, et al(1996) A Ran-domized trial of clarithromycin as prophylaxis against disseminated mycobacterium avium complex infec-tion in patients with advanced acquired immunodefi-ciency syndrome. N Engl J Med 335:384–391PubMedCrossRefGoogle Scholar
  61. 61.
    Havlir DV, Dube MP, Sattler FR, et al(1996) Prophy-laxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 335:392–398PubMedCrossRefGoogle Scholar
  62. 62.
    Currier JS, Williams PL, Koletar SL, et al(2000) Dis-continuation of Mycobacterium avium complex pro-phylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS clinical trials group 362 study team. Ann Intern Med 133:493–503PubMedGoogle Scholar
  63. 63.
    Dworkin MS, Hanson DL, Kaplan JE, et al(2000) Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis 182:611–615PubMedCrossRefGoogle Scholar
  64. 64.
    El Sadr WM, Burman WJ, Grant LB, et al(2000) Dis-continuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Com-munity Programs for Clinical Research on Aids. N Engl J Med 342:1085–1092PubMedCrossRefGoogle Scholar
  65. 65.
    Furrer H, Telenti A, Rossi M, et al(2000) Discontinu-ing or withholding primary prophylaxis against Mycobacterium avium in patients on successful anti-retroviral combination therapy. The Swiss HIV Cohort Study. Aids 14:1409–1412PubMedCrossRefGoogle Scholar
  66. 66.
    Gordin FM, Sullam PM, Shafran SD, et al (1999) A ran-domized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacteri-um avium complex. Clin Infect Dis 28:1080–1085PubMedCrossRefGoogle Scholar
  67. 67.
    Chaisson RE, Benson CA, Dube MP, et al(1994) Clar-ithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clini-cal Trials Group Protocol 157 Study Team. Ann Intern Med 121:905–911PubMedGoogle Scholar
  68. 68.
    Cohn DL, Fisher EJ, Peng GT, et al(1999) A prospec-tive randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in aids patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 29:125–133PubMedCrossRefGoogle Scholar
  69. 69.
    Chaisson RE, Keiser P, Pierce M, et al(1997) Clar-ithromycin and ethambutol with or without clofaz-imine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11:311–317PubMedCrossRefGoogle Scholar
  70. 70.
    Aberg JA, Yajko DM, Jacobson MA (1998) Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacter-ial therapy combined with highly active antiretroviral therapy. J Infect Dis 178:1446–1449PubMedCrossRefGoogle Scholar
  71. 71.
    Kirk O, Lundgren JD, Pedersen C, et al(1999) Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 13:1647–1651PubMedCrossRefGoogle Scholar
  72. 72.
    Soriano V, Dona C, Rodriguez-Rosado R, et al(2000) Discontinuation of secondary prophylaxis for oppor-tunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14:383–386PubMedCrossRefGoogle Scholar
  73. 73.
    Cinti SK, Kaul DR, Sax PE, et al(2000) Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobac-terial agents. Clin Infect Dis 30:511–514PubMedCrossRefGoogle Scholar
  74. 74.
    Horvath KD, Whelan RL (1998) Intestinal tuberculo-sis: return of an old disease. Am J Gastroenterol 93:692–696PubMedCrossRefGoogle Scholar
  75. 75.
    Marshall JB (1993) Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 88:989–999PubMedGoogle Scholar
  76. 76.
    Bini EJ, Weinshel EH, Falkenstein DB (1999) Risk fac-tors for recurrent bleeding and mortality in human immunodeficiency virus infected patients with acute lower GI hemorrhage. Gastrointest Endosc 49:748–753PubMedCrossRefGoogle Scholar
  77. 77.
    Bini EJ, Cohen J (1998) Diagnostic yield and cost-effec-tiveness of endoscopy in chronic human immunodefi-ciency virus-related diarrhea. Gastrointest Endosc 48:354–361PubMedCrossRefGoogle Scholar
  78. 78.
    Bini EJ, Weinshel EH (1998) Endoscopic evaluation of chronic human immunodeficiency virus-related diar-rhea: is colonoscopy superior to flexible sigmoi-doscopy? Am J Gastroenterol 93:56–60PubMedCrossRefGoogle Scholar
  79. 79.
    Anonymous (1998) Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations, centers for disease control and prevention. Mmwr Morb Mortal Wkly Rep 47:1–58Google Scholar
  80. 80.
    Horsburgh CR Jr., Feldman S, Ridzon R (2000) Prac-tice guidelines for the treatment of tuberculosis. Clin Infect Dis 31:633–639PubMedCrossRefGoogle Scholar
  81. 81.
    Santoro-Lopes G, De Pinho AM, Harrison LH, et al (2002) Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 34:543–546PubMedCrossRefGoogle Scholar
  82. 82.
    Girardi E, Antonucci G, Vanacore P, et al(2000) Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infec-tion. AIDS 14:1985–1991PubMedCrossRefGoogle Scholar
  83. 83.
    Jones JL, Hanson DL, Dworkin MS, et al(2000) HIV-associated tuberculosis in the era of highly active anti-retroviral therapy. The Adult/Adolescent Spectrum Of HIV Disease Group. Int J Tuberc Lung Dis 4:1026–1031PubMedGoogle Scholar
  84. 84.
    Girardi E, Palmieri F, Cingolani A, et al(2001) Chang-ing clinical presentation and survival in HIV-associat-ed tuberculosis after highly active antiretroviral thera-py. J Acquir Immune Defic Syndr 26:326–331PubMedGoogle Scholar
  85. 85.
    Leonard MK, Larsen N, Drechsler H, et al(2002) Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 34:1002–1007PubMedCrossRefGoogle Scholar
  86. 86.
    Conti S, Masocco M, Pezzotti P, et al(2000) Differen-tial impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 25:451–458PubMedCrossRefGoogle Scholar
  87. 87.
    Dean GL, Edwards SG, Ives NJ, et al(2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16:75–83PubMedCrossRefGoogle Scholar
  88. 88.
    Waisman JL, Palmero DJ, Alberti FA, et al(2001) Improved prognosis in HIV/AIDS related multi-drug resistant tuberculosis patients treated with highly active antiretroviral therapy. Medicina (B Aires) 61:810–814Google Scholar
  89. 89.
    Mayor AM, Gomez MA, Otero JF, et al(2001) Pul-monary tuberculosis mortality risks in a cohort of HIV/AIDS patients in Puerto Rico. Cell Mol Biol (Noisy-Le-Grand) 47:1143–1148Google Scholar
  90. 90.
    Kunimoto DY, Chui L, Nobert E, et al(1999) Immune mediated’ HAART attack during treatment for tuber-culosis. Highly active antiretroviral therapy. Int J Tuberc Lung Dis 3:944–947PubMedGoogle Scholar
  91. 91.
    John M, French MA (1998) Exacerbation of the inflam-matory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 169:473–474PubMedGoogle Scholar
  92. 92.
    Narita M, Ashkin D, Hollender ES, et al(1998) Para-doxical worsening of tuberculosis following antiretro-viral therapy in patients with AIDS. Am J Respir Crit Care Med 158:157–161PubMedGoogle Scholar
  93. 93.
    Smith MA, Brennessel DJ (1994) Cytomegalovirus. Infect Dis Clin North Am 8:427–438PubMedGoogle Scholar
  94. 94.
    Goodgame RW (1993) Gastrointestinal Cytomegalovirus disease. Ann Intern Med 119:924–935PubMedGoogle Scholar
  95. 95.
    Beaugerie L, Ngo Y, Goujard F, et al(1994) Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroen-terology 107:858–863CrossRefGoogle Scholar
  96. 96.
    Bini EJ, Gorelick SM, Weinshel EH (2000) Outcome of AIDS-associated Cytomegalovirus colitis in the era of potent antiretroviral therapy. J Clin Gastroenterol 30:414–419PubMedCrossRefGoogle Scholar
  97. 97.
    Bini EJ, Micale PL, Weinshel EH (1999) Risk factors for rebleeding and mortality from acute upper gastroin-testinal hemorrhage in human immunodeficiency virus infection. Am J Gastroenterol 94:358–363PubMedCrossRefGoogle Scholar
  98. 98.
    Chalasani N, Wilcox CM (1998) Etiology and outcome of lower gastrointestinal bleeding in patients with AIDS. Am J Gastroenterol 93:175–178PubMedCrossRefGoogle Scholar
  99. 99.
    Dieterich DT, Kim MH, McMeeding A, et al(1991) Cytomegalovirus appendicitis in a patient with acquired immune deficiency syndrome. Am J Gas-troenterol 86:904–906Google Scholar
  100. 100.
    Jacobson MA, Mills J (1988) Serious Cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 108:585–594PubMedGoogle Scholar
  101. 101.
    Kram HB, Hino ST, Cohen RE, et al(1984) Spontaneous colonic perforation secondary to Cytomegalovirus in a patient with acquired immune deficiency syndrome. Crit Care Med 12:469–471PubMedCrossRefGoogle Scholar
  102. 102.
    Murray JG, Evans SJ, Jeffrey PB, et al(1995) Cytomegalovirus colitis in AIDS: CT features. AJR Am J Roentgenol 165:67–71PubMedGoogle Scholar
  103. 103.
    Tatum ET, Sun PC, Cohn DL (1989) Cytomegalovirus vasculitis and colon perforation in a patient with the acquired immunodeficiency syndrome. Pathology 21:235–238PubMedCrossRefGoogle Scholar
  104. 104.
    Wilcox CM, Chalasani N, Lazenby A, et al(1998) Cytomegalovirus colitis in acquired immunodeficien-cy syndrome: a clinical and endoscopic study. Gas-trointest Endosc 48:39–43CrossRefGoogle Scholar
  105. 105.
    Wilcox CM, Rabeneck L, Friedman S (1996) Aga tech-nical review: malnutrition and cachexia, chronic diar-rhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroen-terology 111:1724–1752CrossRefGoogle Scholar
  106. 106.
    Wisser J, Zingman B, Wasik M, et al(1992) Cytomegalovirus pseudotumor presenting as bowel obstruction in a patient with acquired immunodefi-ciency syndrome. Am J Gastroenterol 87:771–774PubMedGoogle Scholar
  107. 107.
    Spector SA, McKinley GF, Lalezari JP, et al(1996) Oral ganciclovir for the prevention of cytomegalovirus dis-ease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 334:1491–1497PubMedCrossRefGoogle Scholar
  108. 108.
    Brosgart CL, Louis TA, Hillman DW, et al(1998) A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of Cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on Aids. Aids 12:269–277PubMedCrossRefGoogle Scholar
  109. 109.
    Feinberg JE, Hurwitz S, Cooper D, et al(1998) A ran-domized, double-blind trial of valaciclovir prophylax-is for cyto megalovirus disease in patients with advanced human immunodeficiency virus infection. Aids Clinical Trials Group Protocol 204/Glaxo Well-come 123-014 International CMV Prophylaxis Study Group. J Infect Dis 177:48–56PubMedCrossRefGoogle Scholar
  110. 110.
    Dieterich DT, Poles MA, Dicker M, et al(1993) Foscar-net treatment of Cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 88:542–548PubMedGoogle Scholar
  111. 111.
    Dieterich DT, Poles MA, Lew EA, et al(1993) Concur-rent use of ganciclovir and foscarnet to treat Cytomegalovirus infection in AIDS patients. J Infect Dis 167:1184–1188PubMedCrossRefGoogle Scholar
  112. 112.
    Dieterich DT, Poles MA, Lew EA, et al(1997) Treat-ment of gastrointestinal Cytomegalovirus infection with twice-daily foscarnet: A pilot study of safety, effi-cacy, and pharmacokinetics in patients with AIDS. Antimicrob Agents Chemother 41:1226–1230PubMedGoogle Scholar
  113. 113.
    Plosker GL, Noble S (1999) Cidofovir: a review of its use in Cytomegalovirus retinitis in patients with AIDS. Drugs 58:325–345PubMedCrossRefGoogle Scholar
  114. 114.
    Anonymous (2001) The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treat-ment of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the ganci-clovir cidofovir Cytomegalovirus retinitis Trial. Am J Ophthalmol 131:457–467CrossRefGoogle Scholar
  115. 115.
    Kirsch LS, Arevalo JF, Chavez DLP, et al(1995) Intravit-real cidofovir (HPMPC) treatment of Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533–542PubMedGoogle Scholar
  116. 116.
    MacDougall DS (1997) Update on cidofovir for CMV retinitis. J Int Assoc Physicians Aids Care 3:18–24Google Scholar
  117. 117.
    Martin DF, Kuppermann BD, Wolitz RA, et al(1999) Oral ganciclovir for patients with Cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340:1063–1070PubMedCrossRefGoogle Scholar
  118. 118.
    Polis MA, Desmet MD, Baird BF, et al(1993) Increased survival of a cohort of patients with acquired immun-odeficiency syndrome and Cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med 94:175–180CrossRefGoogle Scholar
  119. 119.
    Young S, Morlet N, Besen G, et al(1998) High-dose (2000-microgram) intravitreous ganciclovir in the treatment of Cytomegalovirus retinitis. Ophthalmolo-gy 105:1404–1410CrossRefGoogle Scholar
  120. 120.
    Jabs DA, Bolton SG, Dunn JP, et al(1998) Discontinu-ing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretrovi-ral therapy. Am J Ophthalmol 126:817–822PubMedCrossRefGoogle Scholar
  121. 121.
    Jouan M, Saves M, Tubiana R, et al(2001) Discontinu-ation of maintenance therapy for Cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15:23–31PubMedCrossRefGoogle Scholar
  122. 122.
    Torriani FJ, Freeman WR, Macdonald JC, et al(2000) CMV retinitis recurs after stopping treatment in viro-logical and immunological failures of potent antiretro-viral therapy. AIDS 14:173–180PubMedCrossRefGoogle Scholar
  123. 123.
    Deayton JR (2001) Changing trends in cytomegalovirus disease in HIV-infected patients. Herpes 8:37–40PubMedGoogle Scholar
  124. 124.
    Uphold CR, Smith MF, Bender BS (1998) Failure of a prospective trial to detect cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. AIDS Patient Care Stds 12:907–912PubMedCrossRefGoogle Scholar
  125. 125.
    Mitchell SM, Membrey WL, Youle MS, et al(1999) Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 83:652–655PubMedCrossRefGoogle Scholar
  126. 126.
    Doan S, Cochereau I, Guvenisik N, et al(1999) Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol 128:250–251PubMedCrossRefGoogle Scholar
  127. 127.
    Casado JL, Arrizabalaga J, Montes M, et al(1999) Inci-dence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS study group. AIDS 13:1497–1502PubMedCrossRefGoogle Scholar
  128. 128.
    Verbraak FD, Boom R, Wertheim-Van Dillen PM, et al (1999) Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. Br J Ophthalmol 83:1186–1189PubMedCrossRefGoogle Scholar
  129. 129.
    Baril L, Jouan M, Agher R, et al(2000) Impact of high-ly active antiretroviral therapy on onset of Mycobac-terium avium complex infection and Cytomegalovirus disease in patients with AIDS. AIDS 14:2593–2596PubMedCrossRefGoogle Scholar
  130. 130.
    Jalali S, Reed JB, Mizoguchi M, et al(2000) Effect of highly active antiretroviral therapy on the incidence of HIV-related Cytomegalovirus retinitis and retinal detachment. Aids Patient Care Stds 14:343–346PubMedCrossRefGoogle Scholar
  131. 131.
    Varani S, Spezzacatena P, Manfredi R, et al(2000) The incidence of Cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active anti-retroviral therapy. Eur J Epidemiol 16:433–437PubMedCrossRefGoogle Scholar
  132. 132.
    Detels R, Tarwater P, Phair JP, et al(2001) Effective-ness of potent antiretroviral therapies on the inci-dence of opportunistic infections before and after AIDS diagnosis. AIDS 15:347–355PubMedCrossRefGoogle Scholar
  133. 133.
    Jabs DA, Van Natta ML, Kempen JH, et al (2002) Char-acteristics of patients with Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133:48-61Google Scholar
  134. 134.
    Deayton JR, Wilson P, Sabin CA, et al(2000) Changes in the natural history of Cytomegalovirus retinitis fol-lowing the introduction of highly active antiretroviral therapy. AIDS 14:1163–1170PubMedCrossRefGoogle Scholar
  135. 135.
    Reed JB, Briggs JW, McDonald JC, et al(2001) Highly active antiretroviral therapy-associated regression of Cytomegalovirus retinitis: long-term results in a small case series. Retina 21:339–343PubMedCrossRefGoogle Scholar
  136. 136.
    Tanaka M, Yasuoka C, Genka I, et al(2001) Sustained Cytomegalovirus-specific CD4+ T cell response asso-ciated with prevention of recurrence of Cytomegalovirus retinitis without secondary prophy-laxis after highly active antiretroviral therapy in patients with AIDS. AIDS Res Hum Retroviruses 17:1749–1756PubMedCrossRefGoogle Scholar
  137. 137.
    Macdonald JC, Torriani FJ, Morse LS, et al(1998) Lack of reactivation of Cytomegalovirus (CMV) retinitis after stopping cmv maintenance therapy in aids patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 177:1182–1187PubMedCrossRefGoogle Scholar
  138. 138.
    Ruhswurm I, Ries E, Krepier K, et al (1999) Control of Cytomegalovirus retinitis after combination antiretro-viral therapy. Acta Ophthalmol Scand 77:471–473PubMedCrossRefGoogle Scholar
  139. 139.
    Postelmans L, Gerard M, Sommereijns B, et al(1999) Discontinuation of maintenance therapy for CMV retinitis in AIDS patients on highly active antiretrovi-ral therapy. Ocul Immunol Inflamm 7:199–203PubMedCrossRefGoogle Scholar
  140. 140.
    Curi AL, Muralha A, Muralha L, et al(2001) Suspen-sion of anticytomegalovirus maintenance therapy fol-lowing immune recovery due to highly active anti-retroviral therapy. Br J Ophthalmol 85:471–473PubMedCrossRefGoogle Scholar
  141. 141.
    Skiest DJ, Chiller T, Chiller K, et al(2001) Protease inhibitor therapy is associated with markedly pro-longed time to relapse and improved survival in AIDS patients with Cytomegalovirus retinitis. Int J Std AIDS 12:659–664PubMedCrossRefGoogle Scholar
  142. 142.
    Berenguer J, Gonzalez J, Pulido F, et al(2002) Discon-tinuation of secondary prophylaxis in patients with Cytomegalovirus retinitis who have responded to high-ly active antiretroviral therapy. Clin Infect Dis 34:394–397PubMedCrossRefGoogle Scholar
  143. 143.
    Walsh JC, Jones CD, Barnes EA, et al(1998) Increasing survival in aids patients with Cytomegalovirus retini-tis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12:613–618PubMedCrossRefGoogle Scholar
  144. 144.
    Casado JL, Perez-Elias MJ, Marti-Belda P, et al(1998) Improved outcome of Cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 19:130–134PubMedCrossRefGoogle Scholar
  145. 145.
    Murphy EL, Collier AC, Kalish LA, et al(2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135:17–26PubMedGoogle Scholar
  146. 146.
    Johnson SC, Benson CA, Johnson DW, et al(2001) Recurrences of Cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 32:815–819PubMedCrossRefGoogle Scholar
  147. 147.
    Song MK, Karavellas MP, Macdonald JC, et al(2000) Characterization of reactivation of Cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 20:151–155PubMedCrossRefGoogle Scholar
  148. 148.
    Poles MA, Fuerst M, McGowan I, et al(2001) HIV-related diarrhea is multifactorial and fat malabsorp-tion is commonly present, independent of HAART. Am J Gastroenterol 96:1831–1837PubMedCrossRefGoogle Scholar
  149. 149.
    Bini EJ, Micale PL, Weinshel EH (2000) Natural histo-ry of HIV-associated esophageal disease in the era of protease inhibitor therapy. Dig Dis Sci 45:1301–1307PubMedCrossRefGoogle Scholar
  150. 150.
    Ioannidis JP, Collier AC, Cooper DA, et al(1998) Clin-ical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178:349–359PubMedCrossRefGoogle Scholar
  151. 151.
    Conant MA, Schacker TW, Murphy RL, et al(2002) Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J Std Aids 13:12–21PubMedCrossRefGoogle Scholar
  152. 152.
    Schacker T, Hu HL, Koelle DM, et al(1998) Famci-clovir for the suppression of symptomatic and asymp-tomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 128:21–28PubMedGoogle Scholar
  153. 153.
    Safrin S, Crumpacker C, Chatis P, et al(1991) A con-trolled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 325:551–555PubMedCrossRefGoogle Scholar
  154. 154.
    Schacker T, Zeh J, Hu HL, et al(1998) Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 178:1616–1622PubMedCrossRefGoogle Scholar
  155. 155.
    Leung DT, Sacks SL (2000) Current recommendations for the treatment of genital herpes. Drugs 60:1329–1352PubMedCrossRefGoogle Scholar
  156. 156.
    Anonymous (1997) Acyclovir-resistant herpes: expanded access available for cidofovir gel (forvade). AIDS Treat News 5Google Scholar
  157. 157.
    Martinez CM, Luks-Golger DB (1997) Cidofovir use in acyclovir-resistant herpes infection. Ann Pharma-cother 31:1519–1521Google Scholar
  158. 158.
    Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, et al (2000) Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treat-ment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care Stds 14:627–635PubMedCrossRefGoogle Scholar
  159. 159.
    Carrigan DR (1997) Adenovirus infections in immuno-compromised patients. Am J Med 102:71–74PubMedCrossRefGoogle Scholar
  160. 160.
    Janoff EN, Orenstein JM, Manischewitz JF, et al(1991) Adenovirus colitis in the acquired immunodeficiency syndrome. Gastroenterology 100:976–979PubMedGoogle Scholar
  161. 161.
    Khoo SH, Bailey AS, De Jong JC, et al(1995) Aden-ovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epi-demiology. J Infect Dis 172:629–637PubMedCrossRefGoogle Scholar
  162. 162.
    Laughon BE, Druckman DA, Vernon A, et al(1988) Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syn-drome. Gastroenterology 94:984–993PubMedGoogle Scholar
  163. 163.
    Sabroe I, Mchale J, Tait DR, et al(1995) Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Thorax 50:1219–1220PubMedCrossRefGoogle Scholar
  164. 164.
    Hromas R, Clark C, Blanke C, et al(1994) Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 14:663–664PubMedGoogle Scholar
  165. 165.
    Kawakami M, Ueda S, Maeda T, et al(1997) Vidara-bine therapy for virus-associated cystitis after allo-geneic bone marrow transplantation. Bone Marrow Transplant 20:485–490PubMedCrossRefGoogle Scholar
  166. 166.
    Hedderwick SA, Greenson JK, Mcgaughy VR, et al (1998) Adenovirus cholecystitis in a patient with AIDS. Clin Infect Dis 26:997–999PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • Saurabh Mehandru
  • Edmund J. Bini
  • Douglas T. Dieterich

There are no affiliations available

Personalised recommendations